Hygea VCT
9 The Parks, Newton-Le-Willows, Haydock, WA12 0JQ, United Kingdom
Overview
Hygea vct provides investors with access to a diversified portfolio of emerging and established MedTech companies qualifying for investment by a VCT. The board has a strong track record of investing in this area and has a network of personnel with successful P&L responsibility experience in the MedTech sector, both in the UK and internationally. A key feature of the Hygea investment approach is to ensure that portfolio companies are developed as solutions companies i.e. compete on the basis of value provided to customers (not price) by providing better patient outcomes at lower total cost. The effect of this approach is that portfolio companies tend to be focused around medical devices, drug delivery systems, diagnostics and technology based support services - standalone molecule development companies do not generally qualify as solutions companies.
- Total investments
- 4
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Health Care
- Venture Capital
Investment portfolio
- Glide Technologies
Participated · Equity · Feb 2017
Glide Technologies is an Oxford-based pharmaceutical development and device company focused on needle-free administration of solid-dose therapeutics and vaccines via its proprietary Glide SDI® needle-free injector. Its pipeline includes octreotide, teriparatide, exenatide and anthrax and influenza vaccines. The company is led by Interim CEO James Otter. Glide completed a £3.2m ($4.0m) funding round. It will use the funds to complete Phase I clinical trials of its novel solid-dose teriparatide formulation during 2017. Teriparatide is approved for the treatment of osteoporosis and has global sales of over $1.3 billion.
- Glide Pharmaceutical Technologies
Participated · Equity · Feb 2013
Glide Pharma, based in Oxford, develops the Glide SDI® needle-free delivery system for administering solid-dose formulations subcutaneously. The Glide SDI uses a spring mechanism to insert a tiny solid dosage below the skin, where it dissolves and releases the pharmaceutical. The company focuses on both the device and the drug product and is developing in-house therapeutic programmes. It plans to use newly raised capital to scale up manufacturing for its proprietary Glide SDI system, covering both drug product and device. Its in-house programmes include epinephrine and parathyroid hormone. The company is led by CEO Ian Smith and recently completed a £14.0m (approximately $21.4m) funding round to support these activities. Glide Pharma, based in Abingdon, UK, develops needle-free administration technologies for solid-dose therapeutics and vaccines. Its proprietary Glide SDI® solid dose injector completed a successful clinical proof-of-concept demonstrating avoidance of bruising and bleeding associated with needles. The company is advancing a Glide octreotide programme toward clinical development. It plans to use new funds to progress that programme and to continue scale-up of its commercial manufacturing process. Glide has completed four investment rounds, bringing total funding to approximately £10m. The company raised £2.7m in the most recent round, supported by existing institutional and private investors.
- Eykona Medical
Participated · Equity · Sep 2010
Eykona Technologies Ltd is an Oxford, UK–based medical technology company spun out from Isis Innovation Ltd, the University of Oxford’s technology transfer company, in 2007. The company is developing an innovative 3D wound imaging system composed of proprietary software and a purpose-designed camera. It intends to launch its first product in Europe and the US next year. The recent capital infusion of £1.19m will be used to develop the imaging system. Following the investment, Technikos LLP remains the largest shareholder. The shareholder base includes both existing and new investors, including venture funds and business angels.
Team
No current team members are available.